Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70307 ↗At a glance
Beobachtungsstudie in British Journal of Clinical Pharmacology, 2025. Written by Yiting Cai and 6 co-authors. Institution: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Major MEDLINE topics: Mycophenolic Acid, Nephrotic Syndrome, Immunosuppressive Agents. 35 references. Funded by: Wu Jieping Medical Foundation, Medical Road renowned clinical pharmacy research public welfare project, Chinese Youth Medical Innovation Research Scientific Research Project.
Abstract (original language)
Aims
Mycophenolic acid (MPA) effectively reduces relapse in paediatric nephrotic syndrome (NS), yet its pharmacokinetic variability hinders optimal dosing. This study aimed to define risk reference values of MPA area under the concentration–time curve (AUC 0‐12h ) for relapse prevention during maintenance therapy.
Methods
In this retrospective cohort study, 89 paediatric NS patients receiving MPA were enrolled. Factors influencing relapse were evaluated via binary logistic regression. Optimal cut‐off threshold were determined using receiver operating characteristic (ROC) curves, while Kaplan–Meier and Cox regression analyses assessed relapse‐free survival (RFS).
Results
Lower MPA AUC 0‐12h levels strongly correlated with relapse (relapse group: 31.49 vs . non‐relapse: 36.48 μg/h/mL, P < 0.001). Logistic regression confirmed MPA AUC 0‐12h as a protective factor (odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.88–0.99). ROC analysis identified 31.51 μg/h/mL as the optimal risk reference value (sensitivity = 87.5%, specificity = 51.02%). Cox regression further demonstrated subthreshold exposure as an independent relapse risk (hazard ratio [HR] = 0.24, 95% CI: 0.14–0.43, P < 0.001). Subgroup analyses validated this risk reference value across corticosteroid response, relapse frequency and rituximab use, though not in focal segmental glomerulosclerosis.
Conclusions
Maintaining MPA AUC 0‐12h ≥ 31.51 μg/h/mL significantly reduces relapse risk in paediatric NS. Individualized mycophenolate mofetil (MMF) dosing guided by therapeutic drug monitoring is critical for optimizing outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
- Department of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Pharmacy, Zhuhai Center for Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.
ORCID profiles: Pan Chen
Funding
- Wu Jieping Medical Foundation
- Medical Road renowned clinical pharmacy research public welfare project
- Chinese Youth Medical Innovation Research Scientific Research Project
Cite
APA
Cai, Y., Liu, B., Chen, L., Zhang, L., Tang, K., Jiang, X., & Chen, P. (2025). Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70307
Vancouver
Cai Y, Liu B, Chen L, Zhang L, Tang K, Jiang X, et al. Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70307
BibTeX
@article{Cai2025,
author = {Cai, Yiting and Liu, Baojing and Chen, Lizhi and Zhang, Lu and Tang, Kejing and Jiang, Xiaoyun and Chen, Pan},
title = {Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70307}
}
EUVIMED